The understanding that changes in microbiome composition can influence chronic human
diseases and the efficiency of therapies has driven efforts to develop microbiota-centred …

Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat
inflammatory bowel disease (IBD) in the clinical practice. In this review, the principal …

The incidence and prevalence of inflammatory bowel disease (IBD) are increasing
worldwide. Current approved medication for IBD treatment in the clinic mainly includes …

Crohn's disease (CD) is a chronic immune‐mediated inflammatory condition which can
negatively impact a patient's quality of life. The traditional management strategy for CD has …

Inflammatory bowel diseases (IBD) encompass two main entities including ulcerative colitis
and Crohn's disease. Although having a common global pathophysiological mechanism …

Despite huge advances in understanding the molecular basis of IBD, clinical management
has continued to rely on a “trial and error” approach. In addition, a therapeutic ceiling has …

Studying individual data types in isolation provides only limited and incomplete answers to
complex biological questions and particularly falls short in revealing sufficient mechanistic …

Objective Despite being in sustained and stable remission, patients with Crohn's disease
(CD) stopping anti-tumour necrosis factor α (TNFα) show a high rate of relapse (~ 50 …

Crohn's disease (CD) is an inflammatory bowel disease (IBD) with complex clinical
manifestations such as chronic diarrhea, weight loss and hematochezia. Despite the …

Background Despite its efficacy, rational guidance for starting/stopping first-line biologic
treatment in individual paediatric Crohn's disease [CD] patients is needed. We assessed …